Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
Portfolio Pulse from Vandana Singh
Roivant Sciences Ltd (ROIV), founded by Republican presidential candidate Vivek Ramaswamy, is in talks with Roche Holdings AG (RHHBY) for the potential sale of an experimental drug for stomach diseases. The deal could exceed $7 billion. The drug, RVT-3101, is currently in the final Phase 3 testing stage. Roivant obtained the drug through a deal with Pfizer Inc (PFE), which retains a 25% stake in the subsidiary and holds commercial rights outside the U.S. and Japan.
July 14, 2023 | 12:55 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche is in talks with Roivant for a potential $7B drug deal. The deal could expand Roche's portfolio of drugs.
The potential deal with Roivant could expand Roche's portfolio of drugs, which could positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Roivant is in talks with Roche for a potential $7B drug deal. The deal could significantly boost Roivant's revenues.
The potential deal with Roche could bring in significant revenues for Roivant, which could positively impact its stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Pfizer retains a 25% stake in the subsidiary that holds the drug Roivant is discussing with Roche. It's unclear what would happen to Pfizer's stake in the event of a deal.
It's unclear what would happen to Pfizer's stake in the subsidiary in the event of a deal between Roivant and Roche. This uncertainty could lead to neutral or mixed impact on Pfizer's stock price.
CONFIDENCE 60
IMPORTANCE 70
RELEVANCE 70